Current Headlines

  1. Pfizer Receives U.S. FDA Accelerated Approval Of IBRANCE (palbociclib)

    Pfizer Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of IBRANCE (palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease

  2. NeuroPace RNS System Reduces Seizures And Improves Quality Of Life For People With Epilepsy

    NeuroPace, Inc. recently announced that interim results from its ongoing long-term treatment (LTT) study demonstrate the RNS System significantly reduces seizure frequency among adults who have a common form of epilepsy that is difficult to treat with medication

  3. Ligand Signs License Agreement With Sermonix For Lasofoxifene

    Ligand Pharmaceuticals Incorporated announces the signing of a license agreement with Sermonix Pharmaceuticals LLC for the development and commercialization of oral lasofoxifene in the United States and additional territories

  4. SinuSys Corp. To Support Clinical Study Of New Steroid-Eluting Spacer Designed To Improve Sinus Surgery Outcomes

    SinuSys Corp., an innovative sinus health company, recently announced commencement of a new clinical trial studying its proprietary drug-eluting spacer infused with steroids for use following functional endoscopic sinus surgery (FESS)

  5. ENMORE: Antibody Drugs & Novel Biological Summit 2015

    CBI Pharma, a subsidiary of ENMORE, will hold the 5th Antibody Drugs & Novel Biological Summit in Chengdu, China on March 15th-16th, 2015

  6. Enanta Announces 95 percent SVR12 Rate In AbbVie’s Phase 3 Study Of All-Oral Treatment For Hepatitis C Virus In Japanese Patients

    Enanta Pharmaceuticals, Inc., a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, recently announced topline Phase 3 results from the GIFT-1 study, AbbVie’s investigational, all-oral, ribavirin-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBT/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan

  7. FDA Grants Breakthrough Therapy Designation To LentiGlobin For Treatment Of Beta-Thalassemia Major

    bluebird bio, Inc. a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases, recently announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to LentiGlobin BB305 Drug Product for the treatment of transfusion-dependent patients with beta-thalassemia major

  8. Life Science Connect To Launch Rebranding Initiative

    Life Science Connect media group is launching a new branding initiative for its products including Life Science Leader magazine, BioProcess Online, Clinical Leader, Drug Discovery Online, Laboratory Network, Outsourced Pharma, Pharmaceutical Online, Outsourced Pharma West Conference and Exhibition, the CMO Leadership Awards, the CRO Leadership Awards, and the Life Science Training Institute. 

  9. OPKO Submits Investigational New Drug Application To Initiate A Phase 2a Trial For Its Long-Acting Coagulation Factor VIIa-CTP To Treat Hemophilia

    OPKO Health, Inc. announced the submission of an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) to conduct a Phase 2a study of OPKO's long-acting version of coagulation Factor VIIa (Factor VIIa-CTP) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX

  10. PPD Expands Clinical Supplies Facility In Athlone, Ireland

    Pharmaceutical Product Development, LLC (PPD) has completed an expansion of its clinical supplies facility in Athlone, Ireland, that will enable the company to double its packaging warehousing capabilities and quadruple its distribution services

Newsletter Signup
By clicking Sign Me Up, you agree to our Terms and that you have read our Privacy Policy.